TY - JOUR
T1 - Infectious complications and long-term outcomes in patients with diffuse large B-Cell lymphoma and diabetes mellitus
AU - Pasvolsky, Oren
AU - Berger, Tamar
AU - Geiger, Karyn Revital
AU - Akirov, Amit
AU - Bshara, Elias
AU - Raanani, Pia
AU - Gafter-Gvili, Anat
AU - Shochat, Tzippy
AU - Rozovski, Uri
AU - Gurion, Ronit
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Febrile neutropenia (FN) is a major complication in patients with diffuse large B-Cell lymphoma (DLBCL). Diabetes mellitus (DM) has deleterious effects on the immune system resulting in an increased risk of infections. We evaluated patients with DLBCL who started frontline treatment with R-CHOP, and compared outcomes according to presence of DM comorbidity. Between 2013 and 2018, 218 patients with DLBCL were included. 46 patients (21%) had DM. Rate of admissions for FN was higher for patients with DM (0.7 vs. 0.46 admissions/patient, p =.016), also after age and gender-matched subgroup analysis (p =.004). Improved glycemic control during FN hospitalizations was associated with shorter hospitalizations. Metformin was associated with improved median overall survival in diabetic patients (89 vs. 64 months, p =.018). In conclusion, Patients with DLBCL and DM had higher rates of FN hospitalizations. Improved glycemic control during FN hospitalization was associated with shorter length of stay.
AB - Febrile neutropenia (FN) is a major complication in patients with diffuse large B-Cell lymphoma (DLBCL). Diabetes mellitus (DM) has deleterious effects on the immune system resulting in an increased risk of infections. We evaluated patients with DLBCL who started frontline treatment with R-CHOP, and compared outcomes according to presence of DM comorbidity. Between 2013 and 2018, 218 patients with DLBCL were included. 46 patients (21%) had DM. Rate of admissions for FN was higher for patients with DM (0.7 vs. 0.46 admissions/patient, p =.016), also after age and gender-matched subgroup analysis (p =.004). Improved glycemic control during FN hospitalizations was associated with shorter hospitalizations. Metformin was associated with improved median overall survival in diabetic patients (89 vs. 64 months, p =.018). In conclusion, Patients with DLBCL and DM had higher rates of FN hospitalizations. Improved glycemic control during FN hospitalization was associated with shorter length of stay.
KW - Diffuse large B cell lymphoma
KW - Febrile neutropenia
KW - diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85137842834&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2118526
DO - 10.1080/10428194.2022.2118526
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36067523
AN - SCOPUS:85137842834
SN - 1042-8194
VL - 63
SP - 3378
EP - 3384
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -